富衛夥Artem成立TIM Ventures創投基金 投資馬來西亞保險科技和伊斯蘭金融科技初創企業
電訊盈科(00008.HK)主席李澤楷旗下保險公司富衛宣布,與馬來西亞創業投資公司Artem Ventures合作,成立TIM Ventures創投基金,以投資馬來西亞保險科技和伊斯蘭金融科技領域的新興初創企業,基金規模達4,500萬令吉。
該基金旨在成為馬來西亞領先的創新中心,並已投資四家初創企業,其中包括2021年啟動的預加速計劃FWD Start-Up Studio中的獲獎公司,按需訂閱制保險公司Senang;提供伊斯蘭遺產規劃數碼解決方案的線上平台Pewarisan;馬來西亞金融科技公司Du-It;零存款保險機構Blueduck。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.